# Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

> **NCT02633176** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 120 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Capecitabine
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02633176
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2023-01
- **Final completion:** —
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633176, "Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02633176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*